Orion Corporation: Managers’ transactions – Mikael Silvennoinen

ORION CORPORATION

MANAGERS’ TRANSACTIONS

16 NOVEMBER 2023 at 10.15 EET

        

Orion Corporation: Managers’ transactions – Mikael Silvennoinen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Mikael Silvennoinen

Position: Member of the Board/Deputy member

Issuer: Orion Oyj

LEI: 74370029VAHCXDR7B745

Notification type: INITIAL NOTIFICATION

Reference number: 43738/5/4

____________________________________________

Transaction date: 2023-11-15

Venue: XTXE

Instrument type: SHARE

ISIN: FI0009014377

Nature of transaction: DISPOSAL

Transaction details

(1): Volume: 1910 Unit price: 37.86 EUR

Aggregated transactions (1):

Volume: 1910 Volume weighted average price: 37.86 EUR

Orion Corporation

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.